MIJ 821: Developed by Novartis for Treatment Resistant Depression - Global Emerging Insight and Market Forecast 2021-2030 - ResearchAndMarkets.com

The "MIJ 821 - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

MIJ 821 acts as NR2B N-Methyl D-Aspartate receptor modulators and is being developed by Novartis for Treatment Resistant Depression. It was originally developed by Cadent Therapeutics but Novartis licensed exclusively from Cadent in 2015.

"MIJ 821 - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Treatment Resistant Depression in 7 Major Markets. A detailed picture of the MIJ 821 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product.

The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Scope of the Report

• A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
• Elaborated details on regulatory milestones and other development activities have been provided in this report.
• The report also highlights the drug research and development activity details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around MIJ 821.
• The report contains forecasted sales for MIJ 821 till 2030.
• Comprehensive coverage of the late-stage emerging therapies (Phase III) for Treatment Resistant Depression.
• The report also features the SWOT analysis with analyst insights and key findings of MIJ 821.

MIJ 821 Analytical Perspective

In-depth MIJ 821 Market Assessment

This report provides a detailed market assessment of MIJ 821 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

MIJ 821 Clinical Assessment

The report provides the clinical trials information of MIJ 821 covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Treatment Resistant Depression is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence MIJ 821 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Other emerging products for Treatment Resistant Depression are giving market competition to MIJ 821 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of MIJ 821.
• This in-depth analysis of the forecasted sales data of MIJ 821 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the MIJ 821.

Key Questions Answered

• Which company is developing MIJ 821 along with the phase of the clinical study?
• What is the technology utilized in the development of MIJ 821?
• What is the product type, route of administration and mechanism of action of MIJ 821?
• What is the clinical trial status of the study and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MIJ 821 development?
• What are the key designations that have been granted to MIJ 821?
• What is the forecasted market scenario of MIJ 821?
• What is the history of MIJ 821 and what is its future?
• What is the forecasted sales of MIJ 821 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how these are giving competition to MIJ 821?
• Which are the late-stage emerging therapies under development for the treatment of Treatment Resistant Depression?

For more information about this report visit https://www.researchandmarkets.com/r/4bq3lr

View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005740/en/